NDA 209817 · Paratek Pharms
Nuzyra
Omadacycline Tosylate · Intravenous · Tetracycline-class Antibacterial
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: May 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Oct 2, 2018
Approved uses
3
Original approval plus efficacy supplements
Registered trials
21
7 Phase 3, 0 recruiting
FAERS reports
1,716
997 serious, 118 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 29, 2026.
NUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms ( 1 ): Community-acquired bacterial pneumonia (CABP) ( 1.1 ) Acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) 1.1 Community-Acquired Bacterial Pneumonia NUZYRA is indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae , Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae , Haemophilus parainfluenzae , Klebsiella pneumoniae, Legionella pneumophila , Mycoplasma pneumoniae, and Chlamydophila pneumoniae . 1.2 Acute Bacterial Skin and Skin Structure Infections NUZYRA is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms: Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis , Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus , S. intermedius , and S. constellatus ), Enterococcus faecalis , Enterobacter cloacae, and Klebsiella pneumoniae. 1.3 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and...
Mechanism: NUZYRA is an antibacterial drug [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 13, 2026 Supplement 18 · Efficacy LetterLabel
- May 27, 2021 Supplement 10 · Efficacy LetterLabel
- Oct 2, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- NUZYRA · OMADACYCLINE TOSYLATE EQ 100MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Omadacycline" as an intervention, any sponsor and status, largest first.
- Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)Pivotal-lookingCompleted
Paratek Pharmaceuticals IncIndustry
NCT02531438 · 774 participants · Start Nov 2015 · Primary completion Feb 5, 2017
Drug: Omadacycline; Moxifloxacin · For: Bacterial Pneumonia; Community-Acquired Infections
Sites: Birmingham, Alabama; Mobile, Alabama; Laguna Hills, California · 140 sites in all
- Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSIPivotal-lookingCompleted
Paratek Pharmaceuticals IncIndustry
NCT02877927 · 735 participants · Start Aug 2016 · Primary completion May 26, 2017
Drug: Omadacycline; Linezolid · For: Bacterial Infections; Skin Structures and Soft Tissue Infections
Sites: Birmingham, Alabama; Mobile, Alabama; Anaheim, California · 50 sites in all
- Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial PneumoniaPivotal-lookingCompleted
Paratek Pharmaceuticals IncIndustry
NCT04779242 · 670 participants · Start Feb 25, 2021 · Primary completion Mar 27, 2024
Drug: Omadacycline; Moxifloxacin · For: Community-acquired Pneumonia; Bacterial Pneumonia
Sites: Gabrovo, Bulgaria; Lom, Bulgaria; Pernik, Bulgaria · 55 sites in all
- Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)Pivotal-lookingCompleted
Paratek Pharmaceuticals IncIndustry
NCT02378480 · 655 participants · Start Jun 2015 · Primary completion Apr 2016
Drug: Omadacycline; Linezolid · For: Bacterial Infections; Skin Structures and Soft Tissue Infections
Sites: Mobile, Alabama; Chula Vista, California; La Mesa, California · 78 sites in all
- Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)Pivotal-lookingCompleted
Paratek Pharmaceuticals IncIndustry
NCT03716024 · 234 participants · Start Jul 18, 2007 · Primary completion Jan 7, 2008
Drug: PTK 0796; Linezolid · For: Infectious Skin Disease; Bacterial Skin Disease
Sites: Anaheim, California; Buena Park, California; Chula Vista, California · 11 sites in all
- Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of CystitisPivotal-lookingCompleted
Paratek Pharmaceuticals IncIndustry
NCT03425396 · 225 participants · Start Jan 4, 2018 · Primary completion May 15, 2019
Drug: Omadacycline tablets; Nitrofurantoin capsules · For: Uncomplicated Urinary Tract Infection; Cystitis
Sites: Chula Vista, California; La Mesa, California; Los Angeles, California · 23 sites in all
- IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute PyelonephritisPivotal-lookingCompleted
Paratek Pharmaceuticals IncIndustry
NCT03757234 · 201 participants · Start Nov 19, 2018 · Primary completion Jun 26, 2019
Drug: Omadacycline; Levofloxacin and 1 more · For: Acute Pyelonephritis
Sites: Tbilisi, Georgia; Daugavpils, Latvia; Liepāja, Latvia · 31 sites in all
- Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint InfectionPivotal-lookingActive, not recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterAcademic, hospital or other
NCT05753215 · 180 participants (planned) · Start May 9, 2023 · Primary completion Feb 2026
Drug: Omadacycline Pill; Standard of Care · For: Bone Infection; Joint Infection; Bone and Joint Infection
Sites: Torrance, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use454
- nausea268
- vomiting166
- drug ineffective128
- diarrhoea125
- incorrect product administration duration95
- dyspnoea88
- rash86
- fatigue73
- death72
- incorrect dose administered69
- hospitalisation62
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2019 | 35 |
| 2020 | 109 |
| 2021 | 145 |
| 2022 | 152 |
| 2023 | 296 |
| 2024 | 348 |
| 2025 | 399 |
| 2026 | 231 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nuzyra* (Omadacycline Tosylate)
2024 spending
$107M
Beneficiaries
4,748
9,988 claims
Per beneficiary
$22,456
$245.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,447,781 |
| 2021 | $23,584,013 |
| 2022 | $44,132,806 |
| 2023 | $73,196,529 |
| 2024 | $106,622,302 |
Part B: Nuzyra (Omadacycline Tosylate) · HCPCS J0121
2024 spending
$3.7M
Beneficiaries
445
8,697 claims
Per beneficiary
$8,385
2024 ASP limit $3.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,069,624 |
| 2021 | $1,621,501 |
| 2022 | $1,692,373 |
| 2023 | $2,388,812 |
| 2024 | $3,731,518 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Omadacycline for Community-Acquired Bacterial Pneumonia.
Stets R, Popescu M, Gonong JR, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Omadacycline therapy for Mycobacterium abscessus species infections.
Ingram PR, Jones EE, Allen B, et al. · Intern Med J 2023 · Systematic Review, Case Reports
- Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.
Sanders M, Hong E, Chung PS, et al. · Clin Pharmacokinet 2024 · Clinical Trial, Phase IV, Research Support, Non-U.S. Gov't
- Omadacycline Monotherapy in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus: Results From a Phase 2, Double-blind, Randomized, Placebo-controlled Study.
Winthrop KL, Flume PA, Khare R, et al. · Clin Infect Dis 2026 · Randomized Controlled Trial, Clinical Trial, Phase II
- Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence.
Garey KW, Rose W, Gunter K, et al. · Ann Pharmacother 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.
Torres A, Garrity-Ryan L, Kirsch C, et al. · Int J Infect Dis 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Paratek Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.